UY32600A - Formulación en lípidos de un promotor de la apoptosis - Google Patents

Formulación en lípidos de un promotor de la apoptosis

Info

Publication number
UY32600A
UY32600A UY0001032600A UY32600A UY32600A UY 32600 A UY32600 A UY 32600A UY 0001032600 A UY0001032600 A UY 0001032600A UY 32600 A UY32600 A UY 32600A UY 32600 A UY32600 A UY 32600A
Authority
UY
Uruguay
Prior art keywords
lipids
formulation
bcl
oral administration
apoptosis promoter
Prior art date
Application number
UY0001032600A
Other languages
English (en)
Inventor
Fischer Cristina
Heemstra Katherine
Marsh Kennan
Schmitt Eric
Tong Ping
Zhou Deliang
Fickes Michael
David Paul
Haight Anthony
Mayer Peter
Rubin Vitaly
Sanzgiri Yeshwant
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY32600A publication Critical patent/UY32600A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica para administración por vía oral que comprende un sistema de droga-vehículo que contiene un compuesto inhibidor que comprende una proteína de la familia Bcl-2, por ejemplo, ABT-263, en solución en un vehículo sustancialmente no acuoso que comprende al menos un fosfolípido, y un agente solubilizante farmacéuticamente aceptable. La composición es adecuada para una administración por vía oral a un sujeto que lo necesita para el tratamiento de una enfermedad caracterizada por la sobreexpresión de una o más proteínas anti-apoptóticas de la familia Bcl-2s, por ejemplo cáncer.
UY0001032600A 2009-04-30 2010-04-30 Formulación en lípidos de un promotor de la apoptosis UY32600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17424509P 2009-04-30 2009-04-30

Publications (1)

Publication Number Publication Date
UY32600A true UY32600A (es) 2010-12-31

Family

ID=42732500

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032600A UY32600A (es) 2009-04-30 2010-04-30 Formulación en lípidos de un promotor de la apoptosis

Country Status (17)

Country Link
US (1) US20100280031A1 (es)
EP (1) EP2424500A1 (es)
JP (1) JP2012525434A (es)
KR (1) KR20120013416A (es)
CN (1) CN102458361A (es)
AR (1) AR076512A1 (es)
AU (1) AU2010242925A1 (es)
BR (1) BRPI1014368A2 (es)
CA (1) CA2758534A1 (es)
IL (1) IL215473A0 (es)
MX (1) MX2011011526A (es)
RU (1) RU2011148518A (es)
SG (1) SG175147A1 (es)
TW (1) TW201043605A (es)
UY (1) UY32600A (es)
WO (1) WO2010127192A1 (es)
ZA (1) ZA201107593B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
PL2701684T3 (pl) 2011-04-28 2018-09-28 Platform Brightworks Two, Ltd. Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania
CN102836160A (zh) * 2012-10-10 2012-12-26 武汉大学 一种治疗癌症的组合药物
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
AU2020378279A1 (en) 2019-11-05 2022-05-26 AbbVie Deutschland GmbH & Co. KG Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
DE60113731T2 (de) * 2001-01-31 2006-06-29 Pfizer Products Inc., Groton Als inhibitoren von pde4-isozymen geeignete etherderivate
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
PT1888550E (pt) * 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
MX350501B (es) * 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
WO2009073835A1 (en) * 2007-12-06 2009-06-11 Abbott Laboratories Oral compositions of abt-263 for treating cancer
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
MX2011013797A (es) * 2009-06-18 2012-01-30 Abbott Lab Suspension de farmaco estable de nanoparticula.
KR20120085781A (ko) * 2009-09-20 2012-08-01 아보트 러보러터리즈 Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물

Also Published As

Publication number Publication date
WO2010127192A1 (en) 2010-11-04
RU2011148518A (ru) 2013-06-10
SG175147A1 (en) 2011-11-28
IL215473A0 (en) 2011-12-29
CN102458361A (zh) 2012-05-16
KR20120013416A (ko) 2012-02-14
ZA201107593B (en) 2012-06-27
JP2012525434A (ja) 2012-10-22
TW201043605A (en) 2010-12-16
BRPI1014368A2 (pt) 2016-04-05
EP2424500A1 (en) 2012-03-07
AR076512A1 (es) 2011-06-15
CA2758534A1 (en) 2010-11-04
AU2010242925A1 (en) 2011-11-10
MX2011011526A (es) 2011-11-18
US20100280031A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
BRPI1014492A8 (pt) Formação lípida estabilizada de promotor de apoptose
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
UY32600A (es) Formulación en lípidos de un promotor de la apoptosis
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
ES2488407T3 (es) Preparación farmacéutica que contiene lipasa de origen bacteriano
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
UY32599A (es) Formulación oral sólida de abt-263
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
BR112013009093A2 (pt) dispersões sólidas contendo um agente indutor de apoptose
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
ES2720954T3 (es) Formulaciones estabilizadas de estatina
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
MX2012007325A (es) Capsula de abt-263.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127